

Appendix 4C



ASX Release

Appendix 4C – Q2 2022 Quarterly Cash Flow Report

29 July 2022 – Sydney, Australia – Oneview Healthcare PLC (ASX:ONE) (“Oneview” or “the Company”), a global healthcare technology company, today released its Appendix 4C – Quarterly Cashflow report for the quarter ending 30 June 2022 (Q2 FY22).

Financial Highlights

The Company had a net operating cash outflow of €1.98m. The Company continued to make staged payments on large hardware shipments, which are expected to be delivered in Q3, as outlined in the A\$20m capital raise announcement in November 2021. A key component of the growth strategy, specified in the announcement, is to fund up-front hardware payments for orders of the Company's OEM hardware. €0.5m was paid in respect of these up-front payments in the quarter. The sales proceeds from the bulk of these hardware purchases are expected to be received by the Company in Q3 and Q4 of 2022, as the hardware is delivered to client sites.

Other components of the operating cash outflow in the quarter comprised:

- Receipts from customers totalled €1.3m vs €1.6m in prior period (down 19%).
- The Company announced on 14 April 2022 that it had reached a commercial settlement with Regis Aged Care Pty Ltd (a wholly owned subsidiary of Regis Healthcare Limited) in relation to the claim launched by the Company for breach of the Collaboration Agreement between the parties without admission of liability of either party. The cash settlement of A\$2m was received in the quarter and the final legal fees were paid (net proceeds €1.29m).
- Payments in respect of staff costs totalled €2.9m vs. €2.6m in the previous quarter (up 12%). As noted in the capital raise announcement, staff costs were expected to increase at the margin, as a portion of the proceeds was designated to expand the Company's sales and marketing capabilities. This quarter's staff payments also included commission payments in respect of expansion contract signings.
- Admin and corporate costs of €856k were in line with the prior quarter of €869k.

Payments to related parties of the entity and their associates in the quarter were comprised of directors' fees totalling €133,000.

Operational Highlights

- In May, the Company announced an agreement with BJC Health System (“BJC”) to deploy the Oneview platform group wide at BJC, adding 2,441 additional beds to the existing program and extending the Oneview and BJC partnership for a further 6 years. This project has now commenced in 2 locations for BJC's Shiloh and Belleville hospitals and further workshops are to take place in the coming weeks.
- Cardinal Medical in Lancaster, PA, which offers Family Practice and Urgent Care services, signed a 35 bed contract for a TV/Tablet installation in a brand new building, scheduled to open in June 2023. This is a net new client for Oneview.
- This week, the Company received a purchase order for a four year contract for a 65 bed Cloud enterprise deployment from the Loretto Hospital in Chicago.

- The existing Wiebe Tower at Children's Hospital of Omaha commenced an expansion project in May and has added Oneview Set Top Boxes to their existing tablet setup in 94 rooms.
- The installation of 90 additional All In One (AIO) devices was completed at Epworth HealthCare in the quarter. Installations are continuing in Q3.

In addition to successfully maintaining our ISO 27001/27701 accreditations during mandated surveillance audits, Oneview has also achieved the HIPAA seal of compliance, issued from the Compliancy Group. This further enforces Oneview's commitment to ensuring that private health information and overall security is maintained across the organisation.

CEO Outlook

Well documented staff shortages and workforce challenges continue to plague the healthcare system globally. We remain engaged in strategic conversations with major US and Australian health systems, who are exploring how bedside technology can be used to address this crisis by adopting bedside technology to augment physical nursing.

The US Sales pipeline grew by over 100% for the quarter. The Company is seeing a significant increase in interest for bedside technology but is not yet enjoying widespread sales conversion as health systems continue to grapple with these workforce planning issues.

The company hosted an executive roundtable of high-profile nursing leadership in the United States last month that reaffirmed our hypothesis that the pandemic has led to a paradigm shift in the perceived value proposition of bedside technology.

A number of procurement processes are reaching final stages and we expect decisions on several significant opportunities in Q3.

ESG

At the start of last year, the Company committed to a Company-wide initiative around Environmental, Social and Governance and is pleased to report continued progress, as measured against the World Economic Forum universal ESG framework. Details can be found [HERE](#) on our website and will continue to be reported on a quarterly basis.

This announcement has been approved for release by the board of Oneview Healthcare plc.

About Oneview Healthcare plc

For healthcare systems who lead on exemplary care, Oneview Healthcare plc provides digital tools for patients, families and caregivers to improve the care experience. Unifying a facility's systems, content and services into one digital platform with dedicated devices at the point of care, Oneview helps deliver more control for patients and families, more time for care teams, and less complexity for executives and IT teams. Oneview is proud to partner with leading healthcare systems in the US, Australia, the Middle East and Asia to unify the care experience, in 64 hospitals.

Enquiries:

James Fitter, CEO

Helena D'Arcy, CFO

Website : www.oneviewhealthcare.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Oneview Healthcare PLC

ABN

610 611 768

Quarter ended ("current quarter")30th June 2022

Consolidated statement of cash flows	Current quarter €'000	Year to date (6 months) €'000
1. Cash flows from operating activities		
1.1 Receipts from customers	1,270	2,829
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(1,022)	(2,820)
(c) advertising and marketing	(158)	(283)
(d) leased assets	-	-
(e) staff costs	(2,931)	(5,547)
(f) administration and corporate costs	(856)	(1,725)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes (paid)/refunded	(12)	9
1.7 Government grants and tax incentives	-	-
1.8 Legal claim recovery, net of costs	1,288	1,288
1.9 Other (provide details if material)	444	970
1.9 Net cash from / (used in) operating activities	(1,977)	(5,279)

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(19)	(54)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(19)	(54)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(92)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	-	(92)

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	11,845	15,176
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,977)	(5,279)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(19)	(54)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	(92)
4.5	Effect of movement in exchange rates on cash held	164	262
4.6	Cash and cash equivalents at end of period	10,013	10,013

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter €'000	Previous quarter €'000
5.1	Bank balances	10,013	11,845
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	10,013	11,845

6.	Payments to related parties of the entity and their associates	Current quarter €'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	133
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7. Financing facilities	Total facility amount at quarter end €'000	Amount drawn at quarter end €'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	€'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(1,977)
8.2 Cash and cash equivalents at quarter end (item 4.6)	10,013
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	10,013
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	5.1
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer:	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer:	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer:	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:29 July 2022.....

Authorised by: **BY THE BOARD**.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.